The big Covid-19 trials still to report

The anti-IL-6 antibodies were among the first drugs doctors reached for when Covid-19 emerged, but the failure of several trials to establish a clear benefit meant questions around their use lingered. However, last week a 4,000-patient arm of the Recovery trial found a clear mortality benefit in severely ill hospitalised patients for Roche’s Actemra, at least when combined with the steroid dexamethasone.